RxDoctor Payments Data

Laura McAleer-Leavey, MD

Family Medicine · Newport News, VANPI 1063476513

Payments from drug & device makers

$1,481in general payments, 2019–2025

Across 79 payments — averaging $18.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$359
  • Lilly USA, LLC$255
  • Pfizer$162
  • GSK$136
  • Astellas Pharma US Inc$111
  • AbbVie$87
  • plus $373 from 10 others

What the payments were for

  • Food & beverage$1,481100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,481 in reported general payments places this provider in the 70th percentile of 2,553 family medicine providers in Virginia.

See all family medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$276,529
Medicare patients
520
Services billed
6,415

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin117$126,737
OzempicSemaglutide88$109,762
EliquisApixaban52$68,192
TrulicityDulaglutide42$58,758
MounjaroTirzepatide18$41,142
JanuviaSitagliptin Phosphate31$40,780
XareltoRivaroxaban30$24,940
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog35$24,166
Janumet XrSitagliptin Phos/Metformin Hcl25$22,777
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$21,476
MyrbetriqMirabegron24$19,125
FarxigaDapagliflozin Propanediol12$11,194
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr14$9,873
LinzessLinaclotide13$8,999
Lantus SolostarInsulin Glargine,hum.Rec.Anlog69$8,777

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Stiolto Respimat$32$131,900128 claims
Novo NordiskOzempic$359$109,76288 claims
Lilly USA, LLCTrulicity, Mounjaro$255$99,90060 claims
MerckJanuvia, Janumet Xr, Janumet$14$69,74967 claims
PfizerEliquis$162$68,19252 claims
GSKTrelegy Ellipta, Anoro Ellipta$136$31,34930 claims
Astellas Pharma US IncMyrbetriq$111$19,12524 claims
AbbVieLinzess, Synthroid$87$15,700107 claims
AstraZenecaFarxiga$79$11,19412 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$15$3,270365 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,553 family medicine providers in Virginia.

Other family medicine in Newport News

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →